Leqembi lecanemab

Drug Class

Amyloid-beta-directed monoclonal antibody

Mechanism

Lecanemab is a humanized IgG1 monoclonal antibody that selectively binds to soluble amyloid-beta (Abeta) protofibrils, promoting their clearance and preventing deposition into amyloid plaques.

Approved Indication

Treatment of Alzheimer’s disease in patients with mild cognitive impairment or mild dementia stage with confirmed amyloid pathology.

What This Means For Patients

Leqembi is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2023) — Sources
• EMA — Approved (2025) — Sources
• NMPA — Approved (2024) — Sources

Pivotal Clinical Evidence

• Clarity AD — van Dyck et al., N Engl J Med 2023 (NCT03887416) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269s001lbl.pdf
• https://www.eisai.com/news/2024/news202401.html
• https://www.ema.europa.eu/